Day: July 8, 2013

Bayer Initiates Phase III Trial of an Investigational Recombinant Factor VIII

WAYNE, NJ, (July 8, 2013) – Bayer HealthCare today announced the company has started to enroll patients in an international Phase II/III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A in children. The PROTECT VIII (PROphylaxis in hemophilia A patienTs via directly pEgylated long-aCTing rFVIII) Kids trial is designed to […]